{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:31Z","timestamp":1759335271189,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"crossref","award":["2020KY585"],"award-info":[{"award-number":["2020KY585"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s10067-020-05286-y","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T09:02:36Z","timestamp":1594890156000},"page":"1147-1157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The relationship between JAK2(V617F) mutation and dermatomyositis\u2014a case report and literature review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1812-3108","authenticated-orcid":false,"given":"Qin","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuexiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"issue":"7","key":"5286_CR1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292(7):344\u2013347","journal-title":"N Engl J Med"},{"issue":"6","key":"5286_CR2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0190-9622(91)70153-S","volume":"24","author":"RL Euwer","year":"1991","unstructured":"Euwer RL, Sontheimer RD (1991) Amyopathic dermatomyositis (dermatomyositis sine myositis): presentation of six new cases and review of the literature. J Am Acad Dermatol 24(6):959\u2013966","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"5286_CR3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11926-014-0465-0","volume":"16","author":"EE Bailey","year":"2014","unstructured":"Bailey EE, Fiorentino DF (2014) Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep 16(12):465","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"5286_CR4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Tremblay J-L, Goulet J-R, Raymond Y, Sen\u00e9cal J-L (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84(4):231\u2013249","journal-title":"Medicine"},{"issue":"6","key":"5286_CR5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","volume":"58","author":"S Moghadam-Kia","year":"2019","unstructured":"Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV (2019) Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology 58(6):1011\u20131015","journal-title":"Rheumatology"},{"issue":"8","key":"5286_CR6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, Vleugels RA (2016) Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol 152(8):944\u2013945","journal-title":"JAMA Dermatol"},{"key":"5286_CR7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","volume":"100","author":"S Wendel","year":"2019","unstructured":"Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, Voll RE, Thiel J (2019) Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib\u2013a report of two cases. J Autoimmun 100:131\u2013136","journal-title":"J Autoimmun"},{"issue":"1","key":"5286_CR8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273\u2013287","journal-title":"Immunol Rev"},{"issue":"9","key":"5286_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0236-2","volume":"9","author":"M Schieber","year":"2019","unstructured":"Schieber M, Crispino JD, Stein B (2019) Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer J 9(9):1\u201311","journal-title":"Blood Cancer J"},{"issue":"3","key":"5286_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000338831","volume":"128","author":"C Stijnis","year":"2012","unstructured":"Stijnis C, Kroes W, Balkassmi S, Marijt E, Van Rossum A, Bakker E, Vlasveld L (2012) No evidence for JAK2V617F mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder. Acta Haematol 128(3):183\u2013186","journal-title":"Acta Haematol"},{"issue":"2","key":"5286_CR11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1101\/gr.10.2.258","volume":"10","author":"S Germer","year":"2000","unstructured":"Germer S, Holland MJ, Higuchi R (2000) High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 10(2):258\u2013266","journal-title":"Genome Res"},{"issue":"10","key":"5286_CR12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/1947601910397187","volume":"1","author":"SS Jatiani","year":"2010","unstructured":"Jatiani SS, Baker SJ, Silverman LR, Reddy EP (2010) Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 1(10):979\u2013993","journal-title":"Genes Cancer"},{"issue":"5","key":"5286_CR13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bjhh.2014.10.001","volume":"37","author":"RM de Freitas","year":"2015","unstructured":"de Freitas RM, da Costa Maranduba CM (2015) Myeloproliferative neoplasms and the JAK\/STAT signaling pathway: an overview. Rev Bras Hematol Hemoter 37(5):348\u2013353","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"3","key":"5286_CR14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","volume":"96","author":"C Nielsen","year":"2011","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96(3):450\u2013453","journal-title":"Haematologica"},{"key":"5286_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bj\u00f8rn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediat Inflamm 2015:1\u201316","journal-title":"Mediat Inflamm"},{"issue":"1","key":"5286_CR16","doi-asserted-by":"crossref","first-page":"e000197","DOI":"10.1136\/lupus-2016-000197","volume":"5","author":"A Antovic","year":"2018","unstructured":"Antovic A, Sennstr\u00f6m M, Bremme K, Svenungsson E (2018) Obstetric antiphospholipid syndrome. Lupus Sci Med 5(1):e000197","journal-title":"Lupus Sci Med"},{"issue":"7","key":"5286_CR17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, Wang G (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44(7):1051\u20131057","journal-title":"J Rheumatol"},{"issue":"5","key":"5286_CR18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","volume":"24","author":"I Marie","year":"2013","unstructured":"Marie I, Josse S, Decaux O, Diot E, Landron C, Roblot P, Jouneau S, Hatron P-Y, Hachulla E, Vittecoq O (2013) Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 24(5):474\u2013479","journal-title":"Eur J Intern Med"},{"issue":"1012","key":"5286_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/pgmj.2009.089656","volume":"86","author":"M Dugar","year":"2010","unstructured":"Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ (2010) Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 86(1012):79\u201382","journal-title":"Postgrad Med J"},{"issue":"1","key":"5286_CR20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12931-019-1231-7","volume":"20","author":"A Sclafani","year":"2019","unstructured":"Sclafani A, D\u2019Silva K, Little BP, Miloslavsky E, Locascio J, Sharma A, Montesi S (2019) Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. Respir Res 20(1):256","journal-title":"Respir Res"},{"issue":"5","key":"5286_CR21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrrheum.2015.29","volume":"11","author":"P Brito-Zer\u00f3n","year":"2015","unstructured":"Brito-Zer\u00f3n P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA (2015) The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 11(5):301\u2013312","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"5286_CR22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1084\/jem.20041859","volume":"201","author":"S Salomonsson","year":"2005","unstructured":"Salomonsson S, Sonesson S-E, Ottosson L, Muhallab S, Olsson T, Sunnerhagen M, Kuchroo VK, Thor\u00e9n P, Herlenius E, Wahren-Herlenius M (2005) Ro\/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 201(1):11\u201317","journal-title":"J Exp Med"},{"issue":"1","key":"5286_CR23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/03009740310004658","volume":"33","author":"I Sekigawa","year":"2004","unstructured":"Sekigawa I, Seta N, Yamada M, Iida N, Hashimoto H, Ogawa H (2004) Possible importance of immunoglobulin E in foetal loss by mothers with anti-SSA antibody. Scand J Rheumatol 33(1):44\u201346","journal-title":"Scand J Rheumatol"},{"issue":"429","key":"5286_CR24","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","volume":"10","author":"A Prestipino","year":"2018","unstructured":"Prestipino A, Emhardt AJ, Aumann K, O\u2019Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M (2018) Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10(429):eaam7729","journal-title":"Sci Transl Med"},{"issue":"8","key":"5286_CR25","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4049\/jimmunol.1701231","volume":"200","author":"PT Sage","year":"2018","unstructured":"Sage PT, Schildberg FA, Sobel RA, Kuchroo VK, Freeman GJ, Sharpe AH (2018) Dendritic cell PD-L1 limits autoimmunity and follicular T cell differentiation and function. J Immunol 200(8):2592\u20132602","journal-title":"J Immunol"},{"issue":"4","key":"5286_CR26","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/leu.2017.6","volume":"31","author":"G Nishanth","year":"2017","unstructured":"Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schn\u00f6der TM, Just S, Heidel FH, Schl\u00fcter D (2017) Gain of function in Jak2 V617F-positive T-cells. Leukemia 31(4):1000\u20131003","journal-title":"Leukemia"},{"issue":"7","key":"5286_CR27","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.4049\/jimmunol.1101228","volume":"187","author":"LD Lu","year":"2011","unstructured":"Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Mason JL (2011) Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol 187(7):3840\u20133853","journal-title":"J Immunol"},{"issue":"10","key":"5286_CR28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0961203310367660","volume":"19","author":"S Wang","year":"2010","unstructured":"Wang S, Yang N, Zhang L, Huang B, Tan H, Liang Y, Li Y, Yu X (2010) Jak\/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL\/lpr mice. Lupus 19(10):1171\u20131180","journal-title":"Lupus"},{"issue":"9","key":"5286_CR29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40265-014-0240-6","volume":"74","author":"T Hornung","year":"2014","unstructured":"Hornung T, Wenzel J (2014) Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment. Drugs 74(9):981\u2013998","journal-title":"Drugs"},{"key":"5286_CR30","doi-asserted-by":"crossref","unstructured":"Paik JJ, Christopher-Stine L (2017) A case of refractory dermatomyositis responsive to tofacitinib. Seminars in Arthritis Rheum 46 (4): e19","DOI":"10.1016\/j.semarthrit.2016.08.009"},{"issue":"12","key":"5286_CR31","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, Arima M, Maezawa R (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology 57(12):2114\u20132119","journal-title":"Rheumatology"},{"issue":"10","key":"5286_CR32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00393-018-0565-8","volume":"77","author":"J Hornig","year":"2018","unstructured":"Hornig J, Weinhage T, Schmidt L, Buerke B, Schneider U, Pavenst\u00e4dt H, Becker H, Gabri\u00ebls G (2018) Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z Rheumatol 77(10):952\u2013957","journal-title":"Z Rheumatol"},{"key":"5286_CR33","doi-asserted-by":"crossref","unstructured":"Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease. N Engl J Med 381 (3):291\u2013293","DOI":"10.1056\/NEJMc1900045"},{"issue":"26","key":"5286_CR34","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen F-J, Wolf D, Bieber T, Wenzel J (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371(26):2537\u20132538","journal-title":"N Engl J Med"},{"issue":"6","key":"5286_CR35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau L, Su\u00e1rez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, Rodero MP, Hathazi D, Duffy D, Bondet V (2018) JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 141(6):1609\u20131621","journal-title":"Brain"},{"issue":"11","key":"5286_CR36","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","volume":"141","author":"FA Aeschlimann","year":"2018","unstructured":"Aeschlimann FA, Fr\u00e9mond M-L, Duffy D, Rice GI, Charuel J-L, Bondet V, Saire E, Neven B, Bodemer C, Balu L (2018) A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain 141(11):e80","journal-title":"Brain"},{"issue":"6","key":"5286_CR37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.revmed.2020.02.015","volume":"41","author":"C Jalles","year":"2020","unstructured":"Jalles C, Deroux A, Tardieu M, Lugosi M, Viel S, Benveniste O, Colombe B (2020) Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor. Rev Med Interne 41(6):421\u2013424","journal-title":"Rev Med Interne"},{"key":"5286_CR38","doi-asserted-by":"crossref","unstructured":"Fetter T, Niebel D, Bieber T, Wenzel J (2020) Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib. Acta Derm Venereol:100","DOI":"10.2340\/00015555-3481"},{"issue":"3","key":"5286_CR39","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","volume":"142","author":"C Papadopoulou","year":"2019","unstructured":"Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D (2019) Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain 142(3):e8","journal-title":"Brain"},{"issue":"1","key":"5286_CR40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-019-03847-z","volume":"99","author":"M Breccia","year":"2020","unstructured":"Breccia M, Barat\u00e8 C, Benevolo G, Bonifacio M, Elli EM, Guglielmelli P, Maffioli M, Malato A, Mendicino F, Palumbo GA (2020) Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Ann Hematol 99(1):65\u201372","journal-title":"Ann Hematol"},{"key":"5286_CR41","doi-asserted-by":"crossref","unstructured":"Clark JD, Flanagan ME, Telliez J-B (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases: miniperspective. J Med Chem 57 (12):5023\u20135038","DOI":"10.1021\/jm401490p"},{"key":"5286_CR42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243\u20131252","journal-title":"N Engl J Med"},{"key":"5286_CR43","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN (2018) JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research 7","DOI":"10.12688\/f1000research.13167.1"},{"issue":"2","key":"5286_CR44","first-page":"115","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose P, Verstovsek S (2017) JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood J Am Soc Hematol 130(2):115\u2013125","journal-title":"Blood J Am Soc Hematol"},{"issue":"12","key":"5286_CR45","first-page":"2721","volume":"119","author":"A Tefferi","year":"2012","unstructured":"Tefferi A (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood J Am Soc Hematol 119(12):2721\u20132730","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"5286_CR46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O'shea JJ (2016) Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12(1):25\u201336","journal-title":"Nat Rev Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05286-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05286-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05286-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:09:40Z","timestamp":1626390580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05286-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["5286"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05286-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}